Iqvia Holdings Inc. IQV 0.83% is hardly a household name, but its boss made more last year than the chief executive of Johnson & Johnson —or any other big pharmaceutical or biotech company.
Iqvia doesn’t have some blockbuster drug or cutting-edge genetic treatment. It is a data company that collects prescription sales, medical claims and other patient records, and analyzes that information for drugmakers, insurance companies and governments. It also provides testing services to drug companies.
Last year, the Durham, N.C., company paid its CEO, Ari Bousbib, $38 million. J&J, the largest U.S. pharmaceutical company by revenue, paid its CEO, Alex Gorsky, $29.8 million in 2017. J&J had about $76 billion in revenue in 2017, Iqvia’s was about $8 billion.
The two companies delivered similar shareholder gains last year. J&J’s stock-price appreciation plus dividends returned 24.4% to investors, while the smaller company returned 28.7%.
Compensation committees at S&P 500 companies are increasingly tying annual bonuses to measures beyond financial…
The pay gap between CEOs and their employees has widened over the past half decade,…
Chip maker Broadcom gave Hock Tan, its chief executive, a $161 million stock award, instantly…
Elon's Musk's $56 billion pay package's upheaval, a hedge fund sanctioned for failing to preserve…
Disclosures about directors' skills and expertise are increasingly coming under the microscope as investors ramp…
On Jan. 1, several of the nation's biggest companies — including Morgan Stanley, Kraft Heinz,…